Current prostate biopsy interpretation: Criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 6, 2006, Pages 835-843

  Iczkowski, Kenneth A ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYTOKERATIN; CYTOKERATIN 34BETAE12; PROTEIN P63; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER GRADING; CANCER INFILTRATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; NUCLEOLUS; PROSTATE BIOPSY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; CHEMISTRY; CLASSIFICATION; METHODOLOGY; NEEDLE BIOPSY; PATHOLOGY; PRECANCER; PROSTATE; PROSTATE TUMOR;

BIOPSY, NEEDLE; CELL NUCLEUS; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PRECANCEROUS CONDITIONS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745031136     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65:549-553.
2. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199-202.
3. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med. 2000;124:98-107.
4. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol. 1997;21:1489-1495.
5. Cheville JC, Reznicek MJ, Bostwick DG. The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol. 1997;108:633-640.
6. Iczkowski KA, Bassler TJ, Schwob VS, et al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. Urology. 1998;51:749-757.
7. Iczkowski KA, Chen HM, Yang XJ, et al. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology. 2002;60:851-854.
8. Borboroglu PG, Sur RL, Roberts JL, et al. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol. 2001;166:866-870.
9. Fadare O, Wang S, Mariappan MR. Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med. 2004;128:557-560.
10. Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: their predictive values for cancer in current practice. Am J Surg Pathol. 2005;29:1201-1207.
11. Davidson D, Bostwick DC, Qian J, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol. 1995;154:1295-1299.
12. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
13. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol. 2004;121:99-107.
14. Zhou M, Aydin H, Kahane H, et al. How often does alpha-methylacyl-CoA- racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol. 2004;28:239-243,
15. Molinie V, Fromont C, Sibony M, et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17:1180-1190.
16. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol. 2000;114:896-909.
17. Humphrey PA, Kaleem Z, Swanson PE, Vollmer RT. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol. 1998;22:1239-1246.
18. Varma M, Lee MW, Tamboli P, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens: a study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med. 2002;126:554-561.
19. Fine SW, Epstein JI. Minute foci of Gleason score 8-10 on prostatic needle biopsy: a morphologic analysis. Am J Surg Pathol. 2005;29:962-968.
20. Goldstein NS, Qian J, Bostwick DG. Mucin expression in atypical adenomatous hyperplasia of the prostate. Hum Pathol. 1995;46:887-891.
21. Bostwick DG, Wollan P, Adlakha K. Collagenous micronodules in prostate cancer: a specific but infrequent diagnostic finding. Arch Pathol Lab Med. 1995;119:444-447.
22. Anton RC, Chakraborty S, Wheeler TM. The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol. 1998;22:446-449.
23. Ali TZ, Epstein JI. Perineural involvement by benign prostatic glands on needle biopsy [abstract]. Mod Pathol. 2005;18:125A-6A.
24. Tsujimoto Y, Takayama H, Nonomura N, Okuyama A, Aozasa K. Postatrophic hyperplasia of the prostate in Japan: histologic and immunohistochemical features and p53 gene mutation analysis. Prostate. 2002;52:279-87.
25. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17:292-306.
26. Iczkowski KA, Bostwick DG. The pathologist as optimist: cancer grade deflation in prostatic needle biopsies. Am J Surg Pathol. 1998;22:1169-1170.
27. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000;24:477-478.
28. Iczkowski KA, Bostwick DG. Sampling, submission, and report format for multiple prostate biopsies: a 1999 survey. Urology. 2000;55:568-571.
29. College of American Pathologists Recommendations. Prostate gland protocol, revision date 1/2005. Available at: http://www.cap.org/apps/docs/ cancer_ protocols/2005/prostate05_pw.pdf. Accessed October 2005.
30. Lewis JS, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol. 2002;118:442-450.
31. Iczkowski KA, Jones GL, Casella G, et al. Needle core length in sextant biopsy influences prostate cancer detection rate. Urology. 2002;59:698-703.
32. True LD, Wallner K. Why linear extent, not percent, of cancer should be used to measure cancer in needle biopsies [abstract]. Mod Pathol. 2002;15:184A.
33. Reyes AO, Humphrey PA. Diagnostic effect of complete histologic sampling of prostate needle biopsy specimens. Am J Clin Pathol. 1998;109:416-422.
34. Halushka MK, Kahane H, Epstein JI. Negative 34βE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases. Hum Pathol. 2004;35:43-46.
35. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100:2362-2366.
36. Cheng L, Song S, Pretlow TG, et al. Independent origin of multiple tumors from prostate cancer patients [abstract]. Am J Clin Pathol. 1997;108:325.
37. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol. 2004;17:360-379.
38. Alexander EE, Qian J, Wollan PC, et al. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Urology. 1996;47:693-698.
39. Lefkowitz GK, Taneja SS, Brown J, et al. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol. 2002;168:1415-1418.
40. Kronz JD, Allan CH, Shaikh AA, et al. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy; data on men with more than one follow-up biopsy. Am J Surg Pathol. 2001;25:1079-1085.
41. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol. 1997;28:143-148.
42. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47:1-16.
43. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45:3663-3667.
44. Vacanti MP, Jiang Z, Kordunsky L, Li C. Diagnostic utility of cytokeratin 5/6 in differentiation of benign from malignant glands on prostate needle biopsies [abstract]. Mod Pathol. 2005;18:170A.
45. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin (clone 34βE12) antibody. Am J Surg Pathol. 2002;26:1151-1160.
46. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular weight cytokeratins in adenocarcinoma of the prostate gland: a study of 10O cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol. 1999;23:147-152.
47. Googe PB, McGinley KM, Fitzgibbon JF. Anticytokeratin antibody 34βE12 staining prostate carcinoma. Am J Clin Pathol. 1997;107:219-223.
48. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol. 2005;29:874-880.
49. Iczkowski KA, Cheng L, Crawford BG, Bostwick DG. Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34βE12 to discriminate cancer in prostatic epithelium. Mod Pathol. 1999;12:1-4.
50. Xu, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60:1677-1682.
51. Iczkowski KA, Rantazis CG. Overexpression of NSAID-activated gene product in prostate cancer. Int J Surg Pathol. 2003;11:159-166.
52. Jiang Z, Wu CL, Woda BA, et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004;45:218-225.
53. Jiang Z, Fanger GR, Woda BA, et al. Expression of α-methylacyl-CoA racemase (P540S) in various tissues: a study of 761 cases. Hum Pathol. 2003;34:792-796.
54. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
55. Chen Z-ME, Ritter JH, Wang HL. Differential expression of α-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestine. Am J Surg Pathol. 2005;29:890-896.
56. Jiang Z, Fanger GR, Banner BF, et al. A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev. 2003;27:422-426.
57. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of a basal cell cocktail (34βE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004;122:517-523.
58. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34βE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005;123:231-236.